Physician profile

Robert Howard Patton

Internal Medicine · Salinas, CA

NPI 1689659195

$7,789.44

in general payments reported to CMS, 2019-2025

41 companies · $907 in 2025

The $907 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,157.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,402.00 2019-2025
Amgen INC. $961.47 2019-2025 Repatha, Otezla, Evenity
Novo Nordisk INC $785.43 2019-2025 Ozempic, Rybelsus, Wegovy
Astrazeneca Pharmaceuticals LP $728.10 2019-2025 Airsupra, Farxiga
Lilly USA, LLC $579.82 2019-2025 Mounjaro, Zepbound, Jardiance
Glaxosmithkline, LLC. $476.37 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Abbott Laboratories $383.86 2021-2023 Freestyle Libre 3
Bayer Healthcare Pharmaceuticals INC. $322.82 2022-2025
Pfizer INC. $316.59 2019-2025
Mylan Specialty L.P. $212.90 2021-2024 Yupelri
Janssen Pharmaceuticals, INC $177.67 2019-2022
Dexcom, INC. $133.58 2021-2025 Dexcom G6 Transmitter
Merck Sharp & Dohme LLC $121.78 2019-2025 Vaxneuvance, Vaxelis, Gardasil 9
Sanofi-Aventis U.S. LLC $111.62 2019-2023
E.R. Squibb & Sons, L.L.C. $105.89 2021-2025 Eliquis
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Idorsia Pharmaceuticals US INC $103.86 2023 Quviviq
Boehringer Ingelheim Pharmaceuticals, INC. $101.90 2019-2024 Jardiance
Biohaven Pharmaceuticals, INC. $90.96 2021
Biohaven Pharmaceutical Holding Company LTD. $89.46 2022
Kowa Pharmaceuticals America, INC. $71.14 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $59.20 2022
Horizon Therapeutics Plc $52.90 2021-2023 Krystexxa
Boston Scientific Corporation $35.06 2019-2023 Avvigo Guidance System
Sanofi Pasteur INC. $34.52 2021-2022
Teva Pharmaceuticals USA, INC. $30.92 2023 Austedo Xr, Ajovy
Regeneron Healthcare Solutions, INC. $24.45 2019
Genentech USA, INC. $24.09 2019
Viatris Specialty LLC $21.49 2025 Yupelri
Zyla Life Sciences, INC. $20.16 2020
Amag Pharmaceuticals, INC. $19.90 2019
Daiichi Sankyo INC. $19.79 2019
Astellas Pharma US INC $19.34 2019
Allergan, INC. $19.31 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $17.95 2024 Xifaxan
Arbor Pharmaceuticals, INC. $17.94 2019
Philips North America LLC $17.93 2019
Bigfoot Biomedical INC $17.60 2022
Viiv Healthcare Company $17.31 2025 Apretude
Sunovion Pharmaceuticals INC. $14.90 2020
Roche Diagnostics Corporation $14.47 2021
Therapeuticsmd, INC. $12.99 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Howard Patton

$7,789.44

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $907 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/121109/robert-howard-patton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.